The role of DYRK1A in neurodegenerative diseases

FEBS Journal

Volumn 278, Issue 2, 2011, Pages 236-245

  Wegiel, Jerzy ^a   Gong, Cheng Xin ^a   Hwang, Yu Wen ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

synuclein; alternative splicing factor; Alzheimer's disease; amyloid peptide; Down syndrome; DYRK1A; neurodegeneration; tau phosphorylation

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CASEIN KINASE IEPSILON; CYCLIN DEPENDENT KINASE 5; DNA TOPOISOMERASE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN DYRK1A; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; CATALYSIS; CELLULAR DISTRIBUTION; CEREBELLUM CORTEX; CYTOPLASM; CYTOSKELETON; DEGENERATIVE DISEASE; DOWN SYNDROME; GENE OVEREXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MICROTUBULE ASSEMBLY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY;

ANIMALS; DOWN SYNDROME; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; TAUOPATHIES;

EID: 78651061790     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07955.x     Document Type: Review

References (75)

1. Tejedor F, Zhu XR, Kaltenbach E, Ackermann A, Baumann A, Canal I, Heisenberg M, Fischbach KF, &, Pongs O, (1995) Minibrain: a new protein kinase family involved in postembryonic neurogenesis in Drosophila. Neuron 14, 287-301.
2. Kentrup H, Becker W, Heukelbach J, Wilmes A, Schurmann A, Huppertz C, Kainulainen H, &, Joost H-G, (1996) Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII. J Biol Chem 271, 3488-3495.
3. Song W-J, Sternberg LR, Kasten-Sportes C, Van Keuren ML, Chung S-H, Slack AC, Miller DM, Glover TW, Chiang P-W, Lou L, et al. (1996) Isolation of human and murine homologues of the Drosophila minibrain gene: human homolog maps to 21q22.2 in the Down syndrome "critical region". Genomics 38, 331-339.
4. Wisniewski KE, (1990) Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am J Med Genet Suppl 7, 274-281.
5. Wegiel J, Wisniewski HM, Dziewiatkowski J, Popovitch ER, &, Tarnawski M, (1996) Differential susceptibility to neurofibrillary pathology among patients with Down syndrome. Dementia 7, 135-141.
6. Sadowski M, Wisniewski HM, Tarnawski M, Kozlowski P, Lach B, &, Wegiel J, (1999) Neuronal loss in the entorhinal cortex of aged subjects with Down syndrome. Acta Neuropathol 97, 156-164.
7. Galceran J, de Graaf K, Tejedor FJ, &, Becker W, (2003) The MNB/DYRK1A protein kinase: genetic and biochemical properties. J Neurol Transm Suppl 67, 139-148.
8. Becker W, (2008) Dyrk1a. UCSD-Nature Molecule Pages. doi:.
9. Tejedor FJ, &, Hämmerle B, (2010) MNB/DYRK1A: a multiple regulator of neuronal development. FEBS J
10. Lepagnol-Bestel A-M, Zvara A, Maussion G, Quignon F, Ngimbous B, Ramoz N, Imbeaud S, Loe-Mie Y, Benihoud K, Agier N, et al. (2009) DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodeling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. Hum Mol Genet 18, 1405-1414.
11. Wegiel J, Kuchna I, Nowicki K, Frackowiak J, Dowjat K, Silverman WP, Reisberg B, De Leon M, Wisniewski T, Adayev T, et al. (2004) Cell type-and brain structure-specific patterns of distribution of minibrain kinase in human brain. Brain Res 1010, 69-80.
12. Fotaki V, Dierssen M, Alcántara S, Martínez S, Martí E, Casas C, Visa J, Soriano E, Estivill X, &, Arbonés ML, (2002) Dyrk1A haploinsufficiency affects viability and cause developmental delay and abnormal brain morphology in mice. Mol Cell Biol 22, 6636-6647.
13. Becker W, &, Sippl W, (2010) DYRK1A: activation, regulation, and inhibition. FEBS J.
14. Dowjat WK, Adayev T, Kuchna I, Nowicki K, Palminiello S, Hwang YW, &, Wegiel J, (2007) Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci Lett 413, 77-81.
15. Becker W, Weber Y, Wetzel K, Eirmbter K, Tejedor FJ, &, Joost HG, (1998) Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J Biol Chem 273, 25893-25902.
16. Murakami N, Bolton D, &, Hwang YW, (2009) Dyrk1A binds to multiple endocytic proteins required for formation of clathrin-coated vesicles. Biochemistry 48, 9297-9305.
17. Marti E, Altafaj X, Dierssen M, de la Luna S, Fotaki V, Alvarez M, Perez-Riba M, Ferrer I, &, Estivill X, (2003) Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system. Brain Res 964, 250-263.
18. Ferrer I, Barrachina M, Puig B, Martinez de Lagran M, Marti E, Avila J, &, Dierssen M, (2005) Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis 20, 392-400.
19. Wegiel J, Dowjat K, Kaczmarski W, Kuchna I, Nowicki K, Frackowiak J, Mazur Kolecka B, Wegiel J, Silverman WP, Reisberg B, et al. (2008) The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol 116, 391-407.
20. Liu F, Liang Z, Wegiel J, Hwang Y-W, Iqbal K, Grundke-Iqubal I, Ramakrishna N, &, Gong C-X, (2008) Over-expression of Mnb/Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J 22, 3224-3233.
21. Shi J, Zhang T, Zhou C, Chohan MO, Gu X, Wegiel J, Zhou J, Hwang Y-W, Iqbal K, Grundke-Iqbal I, et al. (2008) Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. J Biol Chem 283, 28660-28669.
22. Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X, &, Proud CG, (2001) The kinase DYRK phosphorylates protein-synthesis initiation factor elF2BÎμ at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J 355, 609-615.
23. Liu F, Li B, Tung E-J, Grundke-Iqubal I, Iqbal K, &, Gong C-X, (2007) Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci 26, 3429-3436.
24. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, Schmidt C, Bronson RT, &, Davisson MT, (1995) A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 11, 177-184.
25. Singh TJ, Zaidi T, Grundke-Iqbal I, &, Iqbal K, (1996) Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases. FEBS Lett 358, 4-8.
26. Lovestone S, &, Reynolds CH, (1997) The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78, 309-324.
27. Hanger DP, Betts JC, Loviny TLF, Blackstock WP, &, Anderton BH, (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 71, 2465-2476.
28. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, &, Anderton BH, (2000) Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3β. J Neurochem 74, 1587-1595.
29. Lee VM-Y, Goedert M, &, Trojanowski JQ, (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24, 1121-1159.
30. Gong C-X, Liu F, &, Grundke-Iqbal I, (2005) Post-translational modifications of tau protein in Alzheimer's disease. J Neurol Transm 112, 813-838. (Pubitemid 40655573)
31. Trojanowski JQ, Mawal-Dewan M, Schmidt ML, Martin J, &, Lee VM, (1993) Localization of the mitogen-activated protein kinase ERK in Alzheimer's disease neurofibrillary tangles and senile plaque neurites. Brain Res 618, 333-337.
32. Chin JY, Knowles RB, Schneider A, Drewes D, Mandelkow E-M, &, Hyman BT, (2000) Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. J Neuropathol Exp Neurol 59, 966-971.
33. Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BA, &, Brion J-P, (2002) The active form of glycogen synthase kinase-3β is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol 103, 91-99.
34. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, &, Imahori K, (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3β and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 92, 232-241.
35. Liu W-K, Williams RT, Hall FL, Dickson DW, &, Yen S-H, (1995) Detection of a Cdc2-related kinase associated with Alzheimer paired helical filaments. Am J Pathol 146, 228-238.
36. Schwab C, DeMaggio AJ, Ghoshal N, Binder LI, Kuret J, &, McGeer PL, (2000) Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol Aging 21, 503-510.
37. Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou JF, Antoine E, Cathala G, Brunel C, &, Tazi J, (1996) Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 381, 80-82.
38. Kondo S, Yamamoto N, Murakami T, Okumura M, Mayeda A, &, Imaizumi K, (2004) Tra2 beta, SF2/ASF and SRp30c modulate the function of an exonic splicing enhancer in exon 10 of tau pre-mRNA. Genes Cells 9, 121-130.
39. D'Souza I, &, Schellenberg GD, (2006) Arginine/serine-rich protein interaction domain-dependent modulation of a tau exon 10 splicing enhancer. J Biol Chem 281, 2460-2469.
40. Goedert M, &, Jakes R, (2005) Mutations causing neurodegenerative tauopathies. Biochem Biophys Acta 1739, 240-250.
41. Liu F, &, Gong C-X, (2008) Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener 3, 1-10.
42. Wegiel J, Kaczmarski W, Barua M, Kuchna I, Nowicki K, Wang K-C, Wegiel J, Ma S-Y, Silverman WP, Reisberg B, et al. The link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome. J Neuropathol Exp Neurol (in press).
43. Ryoo SR, Jeong HK, Radnaabazar C, Too JJ, Cho HJ, Lee HW, Kim IS, Cheon YH, Ahn YS, Chung SH, et al. (2007) DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem 2828, 34850-34857.
44. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DMA, Tabaton M, et al. (1996) Presence of soluble amyloid Ã-peptide precedes amyloid plaque formation in Down's syndrome. Nature Med 2, 93-95.
45. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, &, Selkoe DJ, (1996) Sequence of deposition of heterogenous amyloid β-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3, 16-32.
46. Wisniewski HM, Wegiel J, &, Popovitch ER, (1994) Age-associated development of diffuse and thioflavin-S-positive plaques in Down syndrome. Dev Brain Dysfunct 7, 330-339.
47. Zigman WB, Schupf N, Sersen E, &, Silverman W, (1995) Prevalence of dementia in adults with and without Down syndrome. Am J Ment Retard 100, 403-412.
48. Holland AJ, Hon J, Huppert FA, Stevens F, &, Watson P, (1998) Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. Br J Psychol 172, 493-498.
49. Aplin AE, Gibb GM, Jacobsen JS, Gallo JM, &, Anderton BH, (1996) In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J Neurochem 67, 699-707.
50. Suzuki T, Oishi M, Marshak DR, Czernik AJ, Nairn AC, &, Greengard P, (1994) Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. EMBO J 13, 1114-1122.
51. Iijima K, Ando K, Takeda S, Satoh Y, Seki T, Itohara S, Greengard P, Kirino Y, Nairn AC, &, Suzuki T, (2000) Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin dependent kinase 5. J Neurochem 75, 1085-1091.
52. Standen CL, Brownlees J, Grierson AJ, Kesavapany S, Lau KF, McLoughlin DM, &, Miller CC, (2001) Phosphorylation of thr(668) in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by stress-activated protein kinase 1b (Jun N-terminal kinase-3). J Neurochem 76, 316-320.
53. Ryoo SR, Cho HJ, Le HW, Jeong HK, Radnaabazar C, Kim YS, Kim MJ, Son MY, Seo H, Chung SH, et al. (2008) Dual specificity tyrosine (Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J Neurochem 104, 1333-1344.
54. Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahlijanian MK, &, Tsai LH, (2003) APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163, 83-95.
55. Vingtdeux V, Hamdane M, Gompel M, Bégard S, Drobecq H, Ghestem A, Grosjean ME, Kostanjevecki V, Grognet P, Vanmechelen E, et al. (2005) Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiol Dis 20, 625-637.
56. Sakono M, &, Zako T, (2010) Amyloid oligomers: formation and toxicity of Aβ oligomers. FEBS J 277, 1348-1358.
57. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H, Hashimoto R, Tanaka T, Kudo T, Yamagata H, et al. (2007) The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 16, 15-23.
58. Guimera J, Casas C, Estivill X, &, Pritchard M, (1999) Human Minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. Genomics 57, 407-418.
59. Engidawork E, &, Lubec G, (2003) Molecular changes in fetal Down syndrome brain. J Neurochem 84, 895-904. (Pubitemid 36330644)
60. Kim EJ, Sung Y, Lee HJ, Rhim H, Hasegawa M, Iwatsubo T, Min do S, Kim J, Paik SR, &, Chung KC, (2006) Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J Biol Chem 281, 33250-33257.
61. Lippa CF, Schmidt ML, Lee VM, &, Trojanowski J, (1999) Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 45, 353-357.
62. Sitz JH, Baumgärtel K, Hämmerle B, Papadopoulos C, Hekerman P, Tejedor FJ, Becker W, and, Lutz B, (2008) The Down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4. Neuroscience 157, 596-605.
63. Ihara M, Tomimoto H, Kitayama H, Morioka Y, Akiguchi I, Shibasaki H, Noda M, &, Kinoshita M, (2003) Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies. J Biol Chem 278, 24095-24102.
64. Ihara M, Yamasaki N, Hagivara A, Tanigaki A, Kitano A, Hikawa R, Tomimoto H, Noda M, Takanashi M, Mori H, et al. (2007) Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron 53, 519-533.
65. Kinoshita A, Kinoshita M, Akiyama H, Tomimoto H, Akiguchi I, Kumar S, Noda M, &, Kimura J, (1998) Identification of septins in neurofibrillary tangles in Alzheimer's disease. Am J Pathol 153, 1551-1560.
66. Tomlinson BE, &, Kitchener D, (1972) Granulovacuolar degeneration of hippocampal pyramidal cells. J Pathol 106, 165-185.
67. Ball MJ, &, Nuttall K, (1981) Topography of neurofibrillary tangles and granulovacuoles in hippocampi of patients with Down's syndrome: quantitative comparison with normal ageing and Alzheimer's disease. Neuropathol Appl Neurobiol 7, 13-20.
68. Price DL, Altschuler RJ, Struble RG, Casanova MF, Cork LC, &, Murphy DB, (1986) Sequestration of tubulin in neurons in Alzheimer's disease. Brain Res 385, 305-310.
69. Dickson DW, Ksiezak-Reading H, Davies P, &, Yen SH, (1987) A monoclonal antibody that recognizes a phosphorylated epitope in Alzheimer neurofibrillary tangles, neurofilaments and tau proteins immunostains granulovacuolar degeneration. Acta Neuropathol 73, 254-258.
70. Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, Landon M, &, Mayer RJ, (1988) Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibers in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol 155, 9-15.
71. Bain J, McLauchlan H, Elliott M, &, Cohen P., (2003) The specificities of protein kinase inhibitors: an update. Biochem J 371, 199-204.
72. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, &, Cohen P, (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408, 297-315.
73. Xie W, Ramakrishna N, Wieraszko A, &, Hwang YW, (2008) Promotion of neuronal plasticity by (-)-epigallocatechin-3-gallate. Neurochem Res 33, 776-783.
74. Guedj F, Sebrie C, Rivals I, Ledru A, Paly E, Bizot JC, Smith D, Rubin E, Gillet B, Arbones M, et al. (2009) Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS ONE 4, e4606.
75. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, et al. (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25, 8807-8814.